Physician profile
Michael A Degennaro
NPI 1598713786
$2,480.33
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $362 · 2021: $614 · 2022: $565.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.54 | 2019-2022 | |
| Glaxosmithkline, LLC. | $293.12 | 2019-2022 | |
| Mylan Specialty L.P. | $213.52 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $192.09 | 2019 | |
| Jazz Pharmaceuticals INC. | $159.58 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $153.47 | 2020-2022 | |
| Novo Nordisk INC | $113.69 | 2019-2021 | |
| Harmony Biosciences LLC | $101.10 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $87.35 | 2019-2022 | |
| Genzyme Corporation | $86.99 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $79.86 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $65.24 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $64.84 | 2019-2021 | |
| Pfizer INC. | $55.24 | 2019-2021 | |
| Amarin Pharma, INC. | $51.63 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $45.22 | 2019-2020 | |
| Amgen INC. | $42.33 | 2019-2022 | |
| Grifols USA, LLC | $42.12 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.14 | 2021-2022 | |
| Electromed, INC. | $36.27 | 2021 | |
| Lilly USA, LLC | $31.07 | 2021-2022 | |
| Mannkind Corporation | $30.10 | 2022 | |
| Daiichi Sankyo INC. | $29.99 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.79 | 2022 | |
| Abbott Laboratories | $19.40 | 2022 | |
| Advanced Respiratory, INC | $19.25 | 2021 | |
| Medtronic, INC. | $17.40 | 2022 | |
| Ucb, INC. | $16.67 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.47 | 2022 | |
| Covis Pharma Gmbh | $14.84 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.76 | 2019 | |
| United Therapeutics Corporation | $13.25 | 2019 | |
| Sanofi Pasteur INC. | $12.00 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Degennaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.